UPDATE 4th July 2026.  From a presentation at SNMII 2026 “New prospective comparative research suggests that the PET/CT radiopharmaceutical 64Cu-SARTATE may offer significant advantages over 68Ga-DOTATATE for detecting liver foci in patients with known or suspected neuroendocrine tumors (NETs)” click here UPDATE 23rd December 2025. (Originally published Apr 2021).  Phase 3 trial in discussion (clinical trials reference … Continue reading A Diagnostic Imaging Study of 64Cu-SARTATE™ for Neuroendocrine Tumours